Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): EFNS/PNS 2021 Criteria, Subtypes, and Autoimmune Nodopathies
A comprehensive guideline to applying the EFNS/PNS 2021 diagnostic criteria, recognizing the five clinical subtypes, identifying the autoimmune nodopathies as a distinct entity, and navigating IVIG, SCIG, and rituximab treatment selection.
Executive Summary
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic immune-mediated neuropathy, characterized by symmetric proximal and distal weakness with sensory loss progressing or relapsing over at least 8 weeks — the temporal criterion that distinguishes it from acute Guillain-Barre syndrome. The EFNS/PNS 2021 diagnostic criteria combine clinical phenotype with electrodiagnostic demyelination thresholds and recognize five clinical subtypes (typical, distal acquired demyelinating symmetric / DADS, multifocal / MADSAM, pure motor, pure sensory). The 2021 criteria formally separated autoimmune nodopathies (anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186) as a distinct disease entity with distinctive features (rapid severe onset, sensory ataxia, tremor, IgG4 antibodies, IVIG refractoriness, dramatic rituximab response). Treatment of classical CIDP combines IVIG (2 g/kg over 2-5 days induction, then 1 g/kg every 3 weeks maintenance), subcutaneous immunoglobulin (SCIG, Hizentra 0.2-0.4 g/kg weekly), plasma exchange, or corticosteroids as first-line with equivalent efficacy; rituximab is first-line for nodopathies and second-line for refractory typical CIDP.
Table of Contents
S1. Pathophysiology and Clinical Subtypes
CIDP is an acquired immune-mediated demyelinating polyradiculoneuropathy of the peripheral nervous system. The pathophysiology involves T-cell and B-cell-mediated attack against myelin and Schwann cells, with macrophage-mediated demyelination, complement activation, and antibody-mediated injury at multiple sites along peripheral nerves and roots. The result is segmental demyelination producing conduction block, conduction slowing, and prolonged latencies on nerve conduction studies, with secondary axonal loss in chronic disease.
Five Clinical Subtypes (EFNS/PNS 2021)
| Subtype | Frequency | Distinctive Features |
|---|---|---|
| Typical CIDP | ~50% | Symmetric proximal AND distal weakness; sensory involvement; areflexia or hyporeflexia; progression/relapse ≥8 weeks |
| Distal CIDP (DADS — Distal Acquired Demyelinating Symmetric) | ~10% | Distal-predominant symmetric weakness and sensory loss; often associated with anti-MAG IgM monoclonal gammopathy (more accurately paraproteinemic neuropathy); slower response to IVIG |
| MADSAM (Multifocal Acquired Demyelinating Sensory and Motor) / Lewis-Sumner | ~15% | Asymmetric, multifocal sensorimotor deficits resembling mononeuritis multiplex but with demyelinating physiology; upper extremity predominance common |
| Pure motor CIDP | ~10% | Symmetric weakness without sensory involvement; must distinguish from multifocal motor neuropathy (MMN, which is asymmetric and anti-GM1 positive) |
| Pure sensory CIDP (including CISP — chronic immune sensory polyradiculopathy) | ~10% | Sensory ataxia and sensory loss without weakness; CISP variant has prominent ataxia from large fiber sensory loss |
Demographics
- Age: peak 50-70 years; can occur at any age including childhood
- Sex: male predominance approximately 1.5-2:1
- Annual incidence: approximately 1-2 per 100,000
- Prevalence: approximately 5-10 per 100,000 (more common than ALS)
- Family history: rare familial cases; mostly sporadic
Time Course
CIDP differs from acute Guillain-Barre syndrome (GBS) primarily by time course:
- GBS: reaches nadir within 4 weeks of onset (typically 2-4 weeks)
- CIDP: progresses or relapses for at least 8 weeks (often months to years)
- Acute-onset CIDP (A-CIDP): 5-10% of CIDP cases present like GBS initially but continue progressing past 8 weeks, requiring reclassification
- Subacute CIDP: progression between 4-8 weeks may be reclassified depending on continued progression
S2. EFNS/PNS 2021 Diagnostic Criteria
Diagnostic Framework
The EFNS/PNS 2021 criteria operate at three levels: CIDP, possible CIDP, and CIDP not confirmed. Each level requires specific combinations of clinical and electrodiagnostic features.
Clinical Criteria for Typical CIDP
| Clinical Criterion | Requirement |
|---|---|
| Weakness distribution | Symmetric weakness of proximal AND distal muscles in upper and lower extremities |
| Sensory involvement | Sensory loss in distribution consistent with neuropathy |
| Reflexes | Absent or diminished tendon reflexes |
| Time course | Progression or relapsing course over at least 8 weeks |
| Absence of cranial nerve weakness | Cranial nerve involvement supports nodopathy alternative |
Electrodiagnostic Criteria for Demyelination
Demyelinating motor nerve conduction features must be present in at least 2 nerves per specified thresholds:
| Electrodiagnostic Feature | Threshold for Demyelination |
|---|---|
| Prolonged distal motor latency (DML) | >50% of upper limit of normal (ULN) |
| Reduced motor conduction velocity (MCV) | <70% of lower limit of normal (LLN) |
| Prolonged F-wave latency | >20% above ULN (>50% if amplitude greatly reduced) |
| Absent F-waves | In 2 nerves with normal distal amplitude |
| Conduction block (motor) | >50% reduction in CMAP amplitude between proximal and distal stimulation |
| Temporal dispersion | >30% increase in CMAP duration between proximal and distal stimulation |
Levels of Diagnostic Confidence
| Level | Requirements |
|---|---|
| CIDP (definite) | Clinical criteria + electrodiagnostic demyelinating criteria in 2 nerves |
| Possible CIDP | Clinical criteria + demyelinating features in 1 nerve OR clinical criteria + supportive features (CSF, MRI, US, biopsy, treatment response) without 2-nerve electrodiagnostic confirmation |
| CIDP not confirmed | Inadequate clinical or electrodiagnostic features; alternative diagnosis suggested |
Supportive Criteria
- CSF protein elevation (typically >45 mg/dL) with normal cell count (<10 cells/mm3) — albuminocytologic dissociation
- MRI of brachial or lumbosacral plexus showing enlargement and/or gadolinium enhancement of nerve roots or plexus
- Nerve ultrasound showing enlargement of nerves at proximal locations
- Sural nerve biopsy showing onion-bulb formations and demyelination with mononuclear inflammatory infiltrate (rarely required in modern practice)
- Objective response to immunotherapy (IVIG, steroids, or PLEX) within 4-12 weeks
S3. Nerve Conduction Studies, CSF, and Imaging
Optimal NCS Protocol for CIDP Diagnosis
Skilled and comprehensive nerve conduction studies are essential. Standard protocol:
- Motor nerve studies: bilateral median, ulnar, peroneal, and tibial nerves at minimum; use proximal stimulation sites (axillary, supraclavicular, popliteal fossa) to detect conduction block and temporal dispersion
- Sensory nerve studies: bilateral median, ulnar, sural nerves; SNAP amplitudes often reduced or absent in CIDP
- F-wave studies: at least 10 F-waves per nerve; minimum F-wave latency assessment
- Needle EMG: to assess for axonal loss (fibrillations, positive sharp waves) and chronicity (large polyphasic motor units)
- Concentric needle electrodes preferred over monopolar for consistent amplitude measurements
CSF Analysis
CSF examination in CIDP characteristically shows:
- Albuminocytologic dissociation: elevated protein (typically 45-200 mg/dL, sometimes higher) with normal cell count (<10 cells/mm3)
- Cell count >10/mm3 should prompt consideration of alternative diagnoses (HIV, Lyme, sarcoidosis, lymphomatous neuropathy)
- CSF oligoclonal bands typically negative; positive bands suggest alternative diagnosis
- Very high CSF protein (>200 mg/dL) particularly characteristic of nodopathies (especially anti-NF155)
- HIV antibody, Lyme serology, syphilis screen should accompany CSF in atypical cases
MRI of Plexus and Nerve Roots
MRI of the brachial plexus, lumbosacral plexus, and nerve roots with gadolinium contrast is highly supportive when positive:
- Nerve root enlargement at exit foramina
- Brachial or lumbosacral plexus enlargement
- Gadolinium enhancement of nerve roots and plexus
- Hypertrophy of cauda equina in advanced or longstanding disease
- MRI is particularly useful when electrodiagnostic findings are inconclusive (possible CIDP) or when nodopathy with prominent nerve hypertrophy is suspected
Nerve Ultrasound
High-resolution nerve ultrasound (15-22 MHz transducers) is increasingly used as a non-invasive alternative to MRI:
- Cross-sectional area enlargement at characteristic sites (median nerve at forearm, brachial plexus at supraclavicular region)
- Pattern-based scoring systems (Bochum ultrasound score, Padua ultrasound score) help quantify findings
- Useful for follow-up monitoring without contrast or radiation
Nerve Biopsy
Sural nerve biopsy is rarely required in modern practice given the strength of NCS, CSF, MRI, and antibody testing. Indications include:
- Atypical features suggesting alternative diagnosis (vasculitis, amyloidosis, lymphomatous neuropathy)
- Persistent diagnostic uncertainty after comprehensive workup
- Suspected CISP (chronic immune sensory polyradiculopathy) where NCS may be normal
Findings include onion-bulb formations (recurrent demyelination-remyelination), demyelinated fibers with macrophage infiltration, perivascular mononuclear infiltrate, and endoneurial edema. Findings of axonal loss are common in chronic disease.
Required Antibody Panel
Modern CIDP workup requires antibody testing to identify the nodopathy subset that requires different treatment:
| Antibody | Associated Phenotype | Treatment Implication |
|---|---|---|
| Anti-NF155 (neurofascin 155) | Subacute onset, severe weakness, tremor, sensory ataxia, very high CSF protein, IVIG-refractory | Rituximab first-line; dramatic response |
| Anti-CNTN1 (contactin-1) | Rapid onset, severe motor predominant, nephrotic syndrome rarely | Rituximab first-line |
| Anti-Caspr1 (contactin-associated protein 1) | Sensory predominant, neuropathic pain, sometimes cranial nerve | Rituximab first-line |
| Anti-NF186 (neurofascin 186) | Less common; clinical features variable | Rituximab first-line |
| Anti-MAG IgM (paraproteinemic) | DADS phenotype; IgM monoclonal gammopathy | Rituximab; sometimes IVIG; treat underlying paraprotein |
| Anti-GM1 IgM | Multifocal motor neuropathy (MMN), not CIDP | IVIG (steroids worsen MMN); not CIDP treatment |
S4. Autoimmune Nodopathies and Differential Diagnosis
The Autoimmune Nodopathies — A Distinct Entity
The EFNS/PNS 2021 criteria formally separated autoimmune nodopathies from CIDP as a distinct disease entity. This reclassification recognizes that these antibody-defined conditions have fundamentally different pathophysiology, clinical features, and treatment response than classical CIDP.
| Feature | Classical CIDP | Autoimmune Nodopathies |
|---|---|---|
| Antibody | None identified | Anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186 (IgG4 predominant) |
| Onset | Insidious over weeks-months | Rapid (weeks); severe |
| Weakness pattern | Symmetric proximal+distal | Often severe; sometimes distal predominant |
| Sensory ataxia | Variable | Frequent and severe |
| Tremor | Uncommon | Common (especially anti-NF155) |
| Cranial nerves | Uncommon | Occasional |
| CSF protein | Mildly elevated | Very high (often >200 mg/dL) |
| Nerve hypertrophy on US/MRI | Mild | Pronounced |
| IVIG response | 70-80% respond | Poor or absent response |
| Rituximab response | 40-50% (refractory cases) | 70-80% dramatic response |
Differential Diagnosis
| Differential | Distinguishing Features | Decisive Test |
|---|---|---|
| Guillain-Barre syndrome (GBS) | Acute onset (<4 weeks), monophasic; often post-infectious | Time course; serial assessment |
| POEMS syndrome | Organomegaly, endocrinopathy, lambda M-protein, elevated VEGF, sclerotic bone lesions | Serum VEGF + immunofixation + skeletal survey/PET |
| Multifocal motor neuropathy (MMN) | Asymmetric pure motor, conduction block, anti-GM1 IgM; steroids WORSEN MMN | Anti-GM1 IgM + asymmetric pure motor pattern |
| Anti-MAG paraproteinemic neuropathy | DADS phenotype, IgM monoclonal gammopathy, slow onset | SPEP/immunofixation + anti-MAG IgM |
| Hereditary CMT (especially CMT1) | Family history, foot deformity, slowly progressive over years/decades, no relapses | Genetic testing (PMP22, MPZ, GJB1) |
| Vasculitic neuropathy | Mononeuritis multiplex pattern, axonal physiology, systemic vasculitis features | Sural nerve biopsy + ANCA + systemic workup |
| Lymphomatous neuroinfiltration | Pain, asymmetric, B symptoms, MRI/PET nerve uptake | MRI + nerve biopsy + lymphoma workup |
| Diabetic radiculoplexopathy / amyotrophy | Asymmetric, painful, predominantly proximal lower extremity, diabetic | Clinical pattern + diabetes |
| HIV-associated CIDP | HIV infection, CSF pleocytosis (>10 cells/mm3 typical) | HIV testing |
| Lyme polyradiculitis | Endemic exposure, painful, often facial nerve, CSF pleocytosis | Lyme serology + CSF |
| Sarcoid neuropathy | Other sarcoidosis features, ACE, lymphadenopathy | Chest imaging + biopsy |
S5. IVIG, SCIG, Steroids, PLEX, and Rituximab
First-Line Treatment Options
Three first-line options have equivalent efficacy in classical CIDP per multiple randomized trials. Selection individualizes based on tolerability, access, comorbidities, and patient preference.
| Agent | Induction | Maintenance | Comments |
|---|---|---|---|
| IVIG (preferred for most) | 2 g/kg total over 2-5 days | 1 g/kg every 3 weeks OR 0.4 g/kg weekly | Rapid onset; well tolerated; expensive; requires infusion access |
| SCIG (Hizentra / IgPro20) | After IVIG induction | 0.2-0.4 g/kg SC weekly | Approved for CIDP maintenance; equivalent efficacy; home self-administration; better tolerability than IVIG |
| Plasma exchange (PLEX) | 5-7 sessions every other day, 1.5 plasma volume each | Repeat at 2-6 week intervals as needed | Equivalent efficacy; requires central venous access; less practical for chronic maintenance |
| Corticosteroids | Prednisone 60-80 mg PO daily or pulse IV methylprednisolone 500-1000 mg weekly | Gradual taper over 6-12 months; alternate-day dosing preferred for chronic | Effective but long-term toxicity (osteoporosis, diabetes, infection); best for patients who can taper |
SCIG — Increasingly Preferred for Maintenance
Subcutaneous immunoglobulin (SCIG) has emerged as a preferred maintenance modality in modern CIDP practice. Hizentra (IgPro20) is approved for CIDP maintenance based on the PATH trial demonstrating equivalent efficacy to IVIG with improved tolerability and patient autonomy. Advantages:
- Self-administration at home eliminates infusion center visits
- Stable IgG levels avoid “wear-off” effects between IVIG infusions
- Lower systemic adverse event burden (less headache, nausea, infusion reactions)
- Patient quality of life improvement documented
- Cost-effective for long-term maintenance compared to IVIG
Limitations include local injection site reactions (mild and generally well tolerated), need for 1-3 injection sites per dose, and slower onset for acute relapses (IVIG preferred for acute exacerbations even in SCIG-maintained patients).
Second-Line: Rituximab
Rituximab is indicated in two scenarios:
- First-line for autoimmune nodopathies (anti-NF155, CNTN1, Caspr1, NF186) given dramatically better response than IVIG
- Second-line for refractory classical CIDP after failure of IVIG, PLEX, and steroids
Dosing: 1000 mg IV at days 0 and 14, followed by maintenance every 6 months for 18-24 months. Response in nodopathies is typically 70-80 percent; in refractory classical CIDP approximately 40-50 percent. Monitor for B-cell depletion, hypogammaglobulinemia, and PCP prophylaxis with prednisone >20 mg.
Other Second-Line and Refractory Therapies
| Agent | Dosing | Comments |
|---|---|---|
| Cyclophosphamide | IV 750 mg/m2 monthly or oral 1-2 mg/kg daily | Refractory severe disease; substantial toxicity |
| Mycophenolate mofetil | 1000 mg PO BID | Steroid-sparing; modest evidence |
| Azathioprine | 2-3 mg/kg PO daily (check TPMT first) | Older steroid-sparing option |
| Cyclosporine / tacrolimus | Trough-guided dosing | Selected refractory cases |
| Hematopoietic stem cell transplant | Experimental | Severely refractory disease; specialty centers |
| Efgartigimod (FcRn antagonist) | Approved 2024 | Approved for CIDP; reduces IgG levels; alternative for IVIG-refractory |
Treatment Response Assessment
- Initial response assessment at 4-12 weeks after treatment initiation; meaningful improvement in strength (MRC sum score), function (INCAT disability score, Rasch-built Overall Disability Scale), and patient-reported quality of life
- Maintenance reassessment every 6-12 months once stable
- Treatment withdrawal trial after 6-12 months of remission; approximately one-third of patients enter sustained remission allowing therapy discontinuation
- Relapse monitoring with serial neurologic examination and patient self-monitoring; resume or escalate therapy at first signs of recurrence
Adjunctive Supportive Care
- Physical and occupational therapy for strength, balance, mobility, and activities of daily living
- Neuropathic pain management: gabapentin, pregabalin, duloxetine, amitriptyline
- Mobility aids: ankle-foot orthoses for foot drop, walker, wheelchair as needed
- Fatigue management: pacing, exercise programs, sleep optimization
- Mental health support: depression and anxiety common in chronic neuromuscular disease
- Vaccinations: pneumococcal, influenza, COVID-19; avoid live vaccines during immunosuppression
S6. Practice Insights — Lessons from the Neuromuscular Clinic
1. Nodal/paranodal antibody panel on every CIDP at diagnosis, not just refractory
The single highest-yield diagnostic rule in experienced practice has shifted over the past 5 years: experienced clinicians now send the nodal/paranodal antibody panel (anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186) at INITIAL CIDP diagnosis, not only when IVIG fails. The reason is that identifying a nodopathy upfront means starting rituximab directly rather than the typical 12-week IVIG trial that does not work and delays effective therapy. The cost of the antibody panel is trivial against the cost of months of inadequate treatment.
2. IVIG-refractory CIDP = check nodopathy AND POEMS, not just escalate dose
When a CIDP patient fails to respond to first-line IVIG within 12 weeks, experienced practice is to investigate alternative diagnoses before escalating IVIG dose or switching to PLEX. The two most consequential alternative diagnoses are autoimmune nodopathy (rituximab responsive) and POEMS syndrome (lenalidomide-ASCT responsive). The standard workup at IVIG failure includes nodal/paranodal antibody panel, serum and urine immunofixation, serum free light chains, serum VEGF, and FDG-PET. Identifying either entity completely changes management.
3. SCIG transition for any patient on stable IVIG maintenance
In experienced hands, the quality of life difference between IVIG (every 3 weeks at infusion center) and SCIG (home self-administration weekly) is enormous, and SCIG efficacy is equivalent for maintenance. The standard now is to offer SCIG transition to any CIDP patient stable on IVIG maintenance for at least 6 months, particularly those who travel for work, have young families, or struggle with infusion center logistics. The PATH trial established equivalent efficacy and patient quality of life improvement is consistent in experienced practice.
4. Subtype recognition shapes prognosis and treatment selection
The five EFNS/PNS clinical subtypes have substantially different treatment response profiles and prognoses that have implications for counseling and treatment selection. In experienced practice, MADSAM responds well to IVIG and rituximab but slower than typical CIDP; DADS often associated with anti-MAG IgM responds poorly to IVIG but better to rituximab; pure motor must be distinguished from MMN (steroids worsen MMN); pure sensory subtypes have slower clinical response and require patience with treatment trials. Subtype recognition at the first visit shapes the entire management arc.
Personal protocol adjustments beyond the published guideline
- Nodal/paranodal antibody panel at INITIAL CIDP diagnosis, not only refractory. The guideline supports this for refractory cases; experienced practice has shifted to upfront testing because identifying a nodopathy at diagnosis means starting rituximab directly rather than 12 weeks of ineffective IVIG.
- IVIG-refractory = simultaneous nodopathy + POEMS workup. The guideline says consider alternative diagnoses; experienced practice is a simultaneous battery (nodal antibodies + immunofixation + free light chains + VEGF + FDG-PET) sent the same week the IVIG failure is recognized.
- SCIG transition offer to every IVIG-stable patient at 6 months. The guideline supports SCIG as alternative; experienced practice actively offers transition to optimize patient quality of life because efficacy is equivalent and lifestyle benefit is substantial.
- Subtype-specific counseling at diagnosis. Experienced practice spends the first visit ensuring the patient understands which CIDP subtype they have, the expected treatment response timeline, and the prognosis differences, because subtypes have substantially different trajectories that shape patient expectations.
Four-panel personal framework: the five EFNS/PNS 2021 clinical subtypes with relative frequencies (panel 1), the electrodiagnostic demyelination thresholds requiring at least 2 nerves to meet criteria (panel 2), the nodal/paranodal antibody matrix mapping each antibody to its distinctive phenotype and preferred treatment (panel 3), and the treatment selection algorithm with the critical IVIG-refractory branch triggering POEMS and repeat nodopathy workup (panel 4). Approximate ranges; not institutional outcome data.
S7. Frequently Asked Questions
- Unruptured Cerebral Aneurysm Screening: Who, When, and How
- Migraine Prophylaxis: Beta-Blockers, Topiramate, CGRP Monoclonals, Gepants, and Botox for Chronic Migraine
- Aneurysmal Subarachnoid Hemorrhage: Chronic & Long-Term Management
- Brain AVM: Spetzler-Martin Grading, Hemorrhage Risk, and Treatment Decision-Making
- Multiple Sclerosis: Diagnosis, McDonald Criteria, and Disease-Modifying Therapy
- Wernicke Encephalopathy: Caine Criteria, IV Thiamine Dosing, and Korsakoff Prevention